

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

FINANCIAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025

This announcement is issued by Hangzhou Diagens Biotechnology Co., Ltd. (the “**Company**”) pursuant to the Note to Rule 13.49(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Shareholders and potential investors of the Company are reminded that the preliminary results of the Company together with its subsidiaries for the year ended December 31, 2025 (as prescribed by Rule 13.49(1) of the Listing Rules) were included in “Unaudited Preliminary Financial Information for the year ended 31 December 2025” in Appendix IIB to the prospectus of the Company dated March 20, 2026, which is available on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.diagens.com. The annual report of the Company for the year ended December 31, 2025 will be published on the said websites of the Stock Exchange and the Company, and despatched to the shareholders of the Company on or before April 30, 2026.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board and Executive Director

Hong Kong, March 31, 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive directors.